Thrivent Financial for Lutherans Acquires New Position in Twist Bioscience Co. (NASDAQ:TWST)

Thrivent Financial for Lutherans bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 973,713 shares of the company’s stock, valued at approximately $43,992,000.

Several other large investors have also recently modified their holdings of TWST. Signaturefd LLC boosted its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter worth $43,000. Blue Trust Inc. grew its position in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TWST shares. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Barclays dropped their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Robert W. Baird upped their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Stock Up 12.3 %

Shares of Twist Bioscience stock opened at $41.43 on Tuesday. The firm has a market cap of $2.43 billion, a PE ratio of -10.85 and a beta of 1.78. The company’s fifty day simple moving average is $43.98 and its two-hundred day simple moving average is $46.18. Twist Bioscience Co. has a 12-month low of $23.00 and a 12-month high of $60.90.

Insider Buying and Selling

In other news, insider Dennis Cho sold 1,507 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. The trade was a 1.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 over the last quarter. 3.92% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.